Reagan-Udall Post-Market Drug Surveillance Initiative Could Address Patient Web Sites

The post-market drug surveillance program getting under way at the Reagan-Udall Foundation could eventually address methods for analyzing data on drug treatment experiences, including side effects, that are increasingly posted through patient networking sites and blogs, according to project manager Troy McCall.

However, McCall pointed out during a Reagan-Udall-sponsored webinar June 6 that the initial focus of the program, known as Innovation in Medical Evidence Development and Surveillance (IMEDS), will be on developing and validating research methods for post-market drug safety surveillance using insurance claims data and electronic health records (